VELSIPITY Drug Patent Profile
✉ Email this page to a colleague
When do Velsipity patents expire, and when can generic versions of Velsipity launch?
Velsipity is a drug marketed by Pfizer and is included in one NDA. There are seven patents protecting this drug.
This drug has ninety-eight patent family members in twenty-seven countries.
The generic ingredient in VELSIPITY is etrasimod arginine. Two suppliers are listed for this compound. Additional details are available on the etrasimod arginine profile page.
DrugPatentWatch® Generic Entry Outlook for Velsipity
Velsipity will be eligible for patent challenges on October 12, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 12, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VELSIPITY?
- What are the global sales for VELSIPITY?
- What is Average Wholesale Price for VELSIPITY?
Summary for VELSIPITY
International Patents: | 98 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Drug Prices: | Drug price information for VELSIPITY |
What excipients (inactive ingredients) are in VELSIPITY? | VELSIPITY excipients list |
DailyMed Link: | VELSIPITY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VELSIPITY
Generic Entry Date for VELSIPITY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VELSIPITY
Drug Class | Sphingosine 1-phosphate Receptor Modulator |
Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
US Patents and Regulatory Information for VELSIPITY
VELSIPITY is protected by seven US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VELSIPITY is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VELSIPITY
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED
Methods of treating conditions related to the S1Preceptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE
FDA Regulatory Exclusivity protecting VELSIPITY
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VELSIPITY
See the table below for patents covering VELSIPITY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 108349891 | ⤷ Sign Up | |
Japan | 2018504398 | S1P1受容体に関連する状態の処置方法 | ⤷ Sign Up |
Slovenia | 2326621 | ⤷ Sign Up | |
Japan | 2021107425 | 自己免疫障害および炎症性障害の処置において有用な置換型1,2,3,4−テトラヒドロシクロペンタ[b]インドル−3−イル)酢酸誘導体 (SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVE USEFUL IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS) | ⤷ Sign Up |
Australia | 2023200978 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |